No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 15.8x · 10Y median 15.8x · 48th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 8
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:14.167Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Kestra Medical Technologies, Ltd. (KMTS) stock was $28.68 as of Oct 6, 2026, 10:00 AM EDT, up 1.18% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +14.1%
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare.
Medical - Instruments & Supplies · Kirkland, WA
Next Earnings Date
Dec 10, 2026
65 days away
EPS Estimate
-0.61
Revenue Est.
$32.03M
Last Quarter Results
EPS
$-0.46
vs Estimate
$-0.63
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KMTS | $1.68B | $28.68 | +1.18% | +14.11% | N/A | N/A | N/A |
| 2ATEC | $1.65B | $10.74 | +0.20% | -23.11% | -2.26% | +3.88% | vs KMTS |
| 3ALHC | $1.71B | $8.26 | -2.82% | -48.69% | -12.15% | N/A | vs KMTS |
| 4ANIP | $1.64B | $72.33 | -0.34% | -18.95% | +16.86% | +0.51% | vs KMTS |
| 5XRAY | $1.73B | $8.64 | +0.99% | -34.07% | -30.27% | -16.38% | vs KMTS |
| 6GENB | $1.76B | $13.74 | -1.22% | N/A | N/A | N/A | vs KMTS |
forward FY estimate
N/A
$30.97M
vs Estimate
$29.01M
Consensus Rating
Based on 7 analysts
Average Price Target
$30.29
+5.6% upside
Low
$28.00
Current
$28.68
High
$32.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $-0.61 | $-0.61 | $-0.59 | 3 |
| Quarter ending Jan 2027 | $-0.59 | $-0.58 | $-0.57 | 3 |
| Quarter ending Apr 2027 | $-0.52 | $-0.51 | $-0.51 | 1 |
| Quarter ending Jul 2027 | $-0.56 | $-0.56 | $-0.56 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-2.48 | $-2.45 | $-2.42 | 5 |
| FY 2028 | $-2.35 | $-2.11 | $-1.97 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $31.91M | $32.03M | $32.11M | 6 |
| Quarter ending Jan 2027 | $35.34M | $35.43M | $35.47M | 6 |
| Quarter ending Apr 2027 | $42.25M | $42.51M | $42.64M | 5 |
| Quarter ending Jul 2027 | $42.63M | $42.89M | $43.02M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $140.76M | $140.95M | $141.01M | 6 |
| FY 2028 | $190.90M | $195.96M | $201.26M | 6 |
